Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 10/20 | 0.75 |
| ▸ | ELANE | P08246 | 4/20 | 0.68 |
| ▸ | MAPT | P10636 | 4/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.68 |
| ▸ | PIM1 | P11309 | 3/20 | 0.68 |
| ▸ | MEN1 | O00255 | 3/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.68 |
| ▸ | TSHR | P16473 | 2/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.68 |
| ▸ | NPC1 | O15118 | 1/20 | 0.68 |
| ▸ | PTP4A3 | O75365 | 1/20 | 0.68 |
| ▸ | GMNN | O75496 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | ESR1 | P03372 | 1/20 | 0.68 |
| ▸ | TP53 | P04637 | 1/20 | 0.68 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28395686 | 0.89 | ACLY (0.71) | ACLYELANEMAPTALDH1A1PIM1 | |
| SCHEMBL30097984 | 0.89 | ACLY (0.71) | ACLYELANEMAPTALDH1A1PIM1 | |
| SCHEMBL29359680 | 0.89 | MAPT (0.72) | ACLYELANEMAPTALDH1A1PIM1 | |
| SCHEMBL9170655 | 0.89 | MAPT (0.72) | ACLYELANEMAPTALDH1A1PIM1 | |
| SCHEMBL12304029 | 0.88 | ELANE (0.85) | ACLYELANEMAPTALDH1A1PIM1 | |
| SCHEMBL30276368 | 0.86 | ACLY (0.72) | ACLYELANEMAPTALDH1A1PIM1 | |
| SCHEMBL28650629 | 0.86 | ACLY (0.72) | ACLYELANEMAPTALDH1A1PIM1 | |
| SCHEMBL30276367 | 0.86 | ACLY (0.69) | ACLYELANEMAPTALDH1A1PIM1 | |
| SCHEMBL28421429 | 0.86 | ACLY (0.69) | ACLYELANEMAPTALDH1A1PIM1 | |
| SCHEMBL27879740 | 0.86 | ACLY (1.00) | ACLYELANEMAPTALDH1A1PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3943085-A2 | TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION | ETH Zurich (CH) | 2022-01-26 | — | — | EP | claimed |
| US-20210186947-A1 | TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION | ETH ZURICH (CH) | 2021-06-24 | — | — | US | claimed |
| EP-3943085-A2 | TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION | ETH Zurich (CH) | 2022-01-26 | — | — | EP | disclosed |
| US-20210186947-A1 | TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION | ETH ZURICH (CH) | 2021-06-24 | — | — | US | disclosed |
| CN-112826818-A | Application of amentoflavone in preparation of staphylococcus aureus MgrA inhibitor | 吉林大学 | 2021-05-25 | — | — | CN | disclosed |
| EP-3801507-A2 | TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION | ETH Zurich (CH) | 2021-04-14 | — | — | EP | disclosed |
| EP-3421449-B1 | PRODUCTION METHOD FOR 1,1'-BINAPHTHYL DERIVATIVES | UNIV KYOTO (JP) | 2021-03-31 | — | — | EP | disclosed |
| EP-3421449-A1 | PRODUCTION METHOD FOR 1,1'-BINAPHTHYL DERIVATIVE, AND 1,1'-BINAPHTHYL DERIVATIVE | Kyoto University (JP) | 2019-01-02 | — | — | EP | disclosed |
| WO-2017145716-A1 | PRODUCTION METHOD FOR 1,1'-BINAPHTHYL DERIVATIVE, AND 1,1'-BINAPHTHYL DERIVATIVE | 国立大学法人京都大学 | 2017-08-31 | — | — | WO | disclosed |
| WO-1994014427-A2 | USE OF SKYRIN AND ANALOGUES FOR THE TREATMENT OF DIABETES MELLITUS AND PROCESS FOR THEIR PREPARATION | ZYMOGENETICS, INC. (US) | 1994-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210186947-A1 | TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION | TOMM70, TOMM34, TIMM50 | ACLY 1316/4885ELANE 4808/4885MAPT 2071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.